查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1985820

月经症候群（PMS）治疗市场：依治疗方法、产品类型和最终用户划分－2026-2032年全球市场预测

Premenstrual Syndrome Treatment Market by Treatment Type, Product Form, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，月经症候群 (PMS) 治疗市场价值为 18.7 亿美元，预计到 2026 年将成长至 19.6 亿美元，复合年增长率为 5.05%，到 2032 年将达到 26.5 亿美元。

主要市场统计数据
基准年 2025 18.7亿美元
预计年份：2026年 19.6亿美元
预测年份 2032 26.5亿美元
复合年增长率 (%) 5.05%

对不断演变的临床复杂性、患者期望和护理路径进行全面概述，这些因素共同塑造了月经症候群 (PMS) 的治疗策略。

月经症候群（PMS）的症状复杂多样，包括身体不适、情绪障碍和功能障碍，需要多学科协作治疗。近年来，临床研究的进展揭示了荷尔蒙週期、神经传导物质调节和心理社会因素之间的病理学联繫。同时，患者越来越希望获得能够最大限度减少对日常生活影响的个人化干预措施。因此，目前的治疗方案更加多元化，结合了行为疗法、营养补充剂和成熟的药物疗法，旨在解决一系列症状，而非仅仅针对单一症状。

数位科技的应用推动了快速变革，透过引入个人化治疗方法和综合护理模式，正在重塑月经症候群 (PMS) 的治疗。

经月经症候群 (PMS) 的治疗格局正在经历一场变革，这主要得益于技术创新、对个人化照护的重新重视以及临床和消费者健康模式的融合。数位疗法和远端医疗平台能够提供远距认知行为疗法和系统化的生活方式指导，从而扩大非机能性食品疗法的覆盖范围，并有助于提高长期治疗的依从性。同时，营养保健品科学和製剂技术的进步正在提高膳食补充剂的生物利用度和标准化程度，使其成为综合护理计划中可靠的辅助工具。

评估美国关税到 2025 年对月经症候群 (PMS) 治疗供应链的韧性、筹资策略和取得趋势的累积影响。

美国关税政策在2025年之前的变化正在对月经症候群（PMS）治疗药物的供应链和成本结构产生显着影响。对于依赖进口活性药物成分、特殊辅料和营养保健成分的产品而言，这种影响尤其明显。为此，製造商和经销商正试图透过审查筹资策略、优先考虑供应商多元化以及加快库存优化来降低额外进口关税带来的风险。这些营运调整通常包括尽可能暂时转向国内供应商，以及重新谈判供应商协议以承担或转嫁额外的接收成本。

关键的细分洞察揭示了治疗类型、最终用户趋势和产品形式偏好如何相互交织，从而影响 PMS 护理中治疗方法的采用和交付。

对治疗细分市场的详细分析突显了治疗方法选择、护理环境和产品形式如何相互交织，并影响临床应用和患者体验。就治疗方法类型而言，认知行为疗法和结构化生活方式管理等非药物疗法在早期疗育路径中发挥着日益重要的作用。同时，营养补充品占据着一个重要且独特的市场区隔。基于胺基酸衍生物、草药萃取物以及维生素和矿物质的补充剂各有其实证依据和监管要求，这些因素会影响临床医生的接受度和患者的信任度。对于中度至重度症状，按药物类别分類的药物治疗仍然至关重要，其中口服避孕药、GABA类似物和选择性血清素再回收抑制剂构成了临床实践中常用治疗方法的基础。

区域趋势和差异化的战略轨迹正在塑造美洲、欧洲、中东、非洲和亚太地区的治疗重点和取得模式。

区域趋势揭示了美洲、欧洲、中东、非洲和亚太地区在临床实践规范、法规环境和分销基础设施等方面存在不同的战略重点。在美洲，成熟的医疗模式以药物和非药物治疗相结合为特征，而私人和公共保险公司在处方药清单和报销中纳入附加疗法的考虑进一步强化了这一模式。这种情况有助于产生证据，证明具有功能性益处和成本效益的治疗路径能够减少后续药物的使用。

PMS治疗生态系统中企业的竞争考察和策略洞察：优势、合作机会、监管差异化因素以及差距识别

在月经症候群 (PMS) 治疗领域，竞争地位更取决于产品组合的深度、证据的可靠性和跨通路伙伴关係，而非单一产品的突破性进展。在荷尔蒙和神经调节药物领域拥有成熟产品组合的製药公司，透过将临床试验结果与真实世界的用药依从性计画以及与临床医生的合作相结合，保持其优势。同时，能够证明其原材料来源稳定、批次间品质一致性以及临床级配方能力的专业营养补充剂生产商和合约开发公司，对临床医生和大规模经销商的吸引力也日益增强。从远距治疗平台到数位化症状追踪器，技术驱动型供应商正透过整合行为介入、临床监督和数据收集等功能来脱颖而出。

为行业领导者提供可操作的策略建议，以加速采用、优化获取途径，并在 PMS 治疗和服务交付中提供综合价值。

产业领导者应优先考虑一系列合作倡议，以加速产品应用、维持市场可近性，并在临床和商业管道中创造永续价值。首先，投资于高品质的实证研究，将介入措施与功能性结果联繫起来，有助于增强与临床医生和保险公司的合作关係，并促进产品融入日常诊疗流程。其次，开发可与药物治疗和补充剂产品联合使用的互通性数位工具和远端医疗项目，有助于提高患者的用药依从性，并支持长期疗效评估。此外，还应辅以稳健的生产和供应链策略，以减少对单一来源进口的依赖，并增强应对力关税和贸易政策变化的能力。

本文檔概述了一种高度透明的多方法调查方法，包括检验、专家检验和资料收集分析框架，构成了 PMS 治疗分析的基础。

本分析采用多方法研究策略，优先考虑对一级资讯来源和二级资讯来源进行检验和有效性检验。一级资讯来源包括对临床医生、药房经理、采购专家和技术提供者的结构化访谈，旨在了解他们对治疗效果、给药挑战和推广应用驱动因素的实际观点。二级资讯来源包括同行评审的临床文献、监管指导文件、产品标籤和公开的临床试验註册信息，以支持对作用机制、安全性特征和治疗定位的阐述。在资料整合过程中，我们运用主题分析来识别重复出现的模式，并采用比较评估来揭示区域差异。

我们进行最终的综合分析，将临床趋势、监管影响和市场趋势结合起来，为 PMS 护理领域的相关人员制定可操作的下一步措施。

总而言之，月经症候群（PMS）治疗格局的演变以向以患者为中心的综合治疗模式转变为特征，这种模式结合了行为疗法、营养补充剂和药物治疗。临床实务和治疗方式的创新正在拓宽有效介入措施的范围，同时也提高了实证医学、品质和互通性的标准。政策和贸易因素凸显了建立具有韧性的供应链和灵活筹资策略的必要性，而区域间法规和治疗模式的差异则强调了製定个人化方案而非统一部署的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗方法月经症候群（PMS）治疗市场

  • 非药物治疗
    • 认知行为疗法
    • 生活方式管理
    • 营养补充品
      • 胺基酸衍生物
      • 草药萃取物
      • 维生素和矿物质
  • 药物治疗

第九章：月经症候群（PMS）治疗市场：依产品形式划分

  • 胶囊
  • 口服液
  • 药片

第十章：月经症候群（PMS）治疗市场：依最终用户划分

  • 居家照护设施
  • 医院
  • 专科诊所

第十一章月经症候群（PMS）治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章月经症候群（PMS）治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章月经症候群（PMS）治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国月经症候群（PMS）治疗市场

第十五章：中国月经症候群（PMS）治疗市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bayer AG
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-4F1ADAF481D9

The Premenstrual Syndrome Treatment Market was valued at USD 1.87 billion in 2025 and is projected to grow to USD 1.96 billion in 2026, with a CAGR of 5.05%, reaching USD 2.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.87 billion
Estimated Year [2026] USD 1.96 billion
Forecast Year [2032] USD 2.65 billion
CAGR (%) 5.05%

Comprehensive contextual overview of the evolving clinical complexities patient expectations and care pathways shaping premenstrual syndrome treatment strategies

Premenstrual syndrome continues to present a complex constellation of symptoms that span physical discomfort, mood disturbance, and functional impairment, demanding multidisciplinary attention. Recent advances in clinical understanding have clarified pathophysiologic pathways that link hormonal cycling, neurotransmitter modulation, and psychosocial triggers, while patient expectations increasingly favor individualized and minimally disruptive interventions. Consequently, care pathways now reflect a broader palette of options that combine behavioral strategies, nutraceuticals, and established pharmacotherapies to address symptom clusters rather than single complaints.

Moreover, health systems and clinicians are responding to shifting patient preferences by integrating remote monitoring, stepped-care protocols, and clearer diagnostic criteria to reduce time to intervention. These trends are amplifying demand for evidence-backed therapeutic alternatives that balance efficacy, tolerability, and real-world usability. As a result, stakeholders from product developers to service providers are reframing clinical value propositions to emphasize measurable improvements in daily functioning, adherence-friendly formats, and interventions that complement rather than replace standard medical care. Taken together, these developments set the stage for more nuanced service models and commercial approaches that prioritize patient-centric outcomes and scalable delivery mechanisms.

Rapid transformative shifts driving digital enablement personalized therapeutic approaches and integrated care models reshaping premenstrual syndrome treatment

The landscape for premenstrual syndrome treatment is undergoing transformative shifts driven by technological innovation, a renewed focus on personalized care, and the convergence of clinical and consumer health paradigms. Digital therapeutics and telehealth platforms are enabling remote cognitive behavioral therapy and structured lifestyle coaching, which in turn are expanding access to non-pharmacological interventions and supporting long-term adherence. Simultaneously, advances in nutraceutical science and formulation techniques are improving the bioavailability and standardization of supplements, thereby making them more credible adjuncts within comprehensive care plans.

In parallel, pharmacological innovation is being informed by deeper insights into neuroendocrine modulation, with clinicians more readily combining established drug classes with targeted behavioral interventions to optimize benefit-risk profiles. Health systems are also experimenting with integrated care pathways that embed symptom tracking, outcome measurement, and stepped escalation protocols to better match intervention intensity to patient needs. These shifts are creating new strategic imperatives for developers and providers: investments in digital enablement, real-world evidence generation, and collaborative care frameworks are becoming essential to differentiate therapeutic offerings and to demonstrate tangible value across diverse payers and delivery settings.

Assessment of the cumulative impact of United States tariffs through 2025 on supply chain resilience procurement strategies and access dynamics for PMS treatments

Tariff policy changes in the United States through 2025 have exerted a measurable influence on the supply chains and cost structures that underpin premenstrual syndrome treatment delivery, particularly for products that rely on internationally sourced active pharmaceutical ingredients, specialty excipients, and imported nutraceutical components. Manufacturers and distributors have responded by reassessing sourcing strategies, prioritizing supplier diversification, and accelerating inventory optimization to mitigate exposure to incremental import duties. These operational adjustments have, in many cases, led to temporary reallocation of sourcing to domestic suppliers where feasible and to renegotiation of supplier agreements to absorb or pass through incremental landed costs.

At the same time, clinical service models and end users have adapted to preserve access and affordability. Hospitals and specialty clinics have tightened procurement protocols and emphasized therapeutic equivalence assessments to maintain continuity of care despite potential price movement in specific product lines. Home care models and remote dispensing have gained traction as stakeholders seek to preserve adherence while minimizing cost inflation associated with facility-based supply chains. Ultimately, the tariff environment has reinforced the importance of flexible manufacturing, transparent cost modeling, and regulatory foresight for companies engaged in developing or delivering treatments for premenstrual syndrome, prompting a strategic focus on resilience rather than short-term repricing.

Key segmentation insights revealing how treatment type end-user dynamics and product form preferences converge to determine therapeutic adoption and delivery for PMS care

A granular view of treatment segmentation highlights how therapeutic choices, care settings, and product formats intersect to shape clinical adoption and patient experience. When considering treatment type, non-pharmacological approaches such as cognitive behavioral therapy and structured lifestyle management play an increasingly central role in early intervention pathways, while nutritional supplements occupy a distinct niche where formulation matters; supplements based on amino acid derivatives, herbal extracts, and vitamins and minerals each present unique evidence requirements and regulatory considerations that influence clinician acceptance and patient trust. Conversely, pharmacological treatments organized by drug class remain essential for moderate to severe symptom profiles, with combined oral contraceptives, GABA analogs, and selective serotonin reuptake inhibitors forming the backbone of therapeutic regimens used in clinical practice.

End-user contexts further modulate preference and delivery: home care settings favor interventions that enable self-administration and remote support, hospitals prioritize acute symptom control and multidisciplinary coordination, and specialty clinics often serve as centers for tailored regimens and advanced therapeutic sequencing. Product form influences adherence and formulation strategy; capsules, oral liquids, and tablets each present distinct advantages related to dosing flexibility, palatability, and stability, which in turn inform product development priorities. Integrating these segmentation dimensions reveals that successful offerings will address evidence thresholds for specific therapeutic classes while aligning product form and delivery models to the operational realities of home care, hospital, and specialty clinic settings.

Regional dynamics and differentiated strategic trajectories across the Americas Europe Middle East & Africa and Asia-Pacific that shape treatment priorities and access models

Regional dynamics reveal differentiated strategic priorities driven by clinical practice norms, regulatory environments, and distribution infrastructures across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, care models are characterized by a mature mix of pharmacological and non-pharmacological adoption augmented by private and public payer considerations that influence formulary placement and reimbursement of adjunctive therapies. This context incentivizes evidence generation that demonstrates functional benefits and cost-effective care pathways that reduce downstream utilization.

Across Europe, the Middle East and Africa, fragmented regulatory frameworks and diverse payer landscapes create complex entry barriers but also enable region-specific innovation, particularly where telehealth and community-based delivery can expand reach. Local manufacturing capabilities and regulatory harmonization efforts are pivotal in determining which product forms and supplements gain traction. Meanwhile, the Asia-Pacific region combines rapidly expanding digital infrastructure with strong demand for nutraceuticals and culturally embedded herbal approaches, and this is complemented by accelerated adoption of remote care models and consumer-facing health technologies. Taken together, these regional trajectories suggest that companies must tailor regulatory strategies, evidence packages, and distribution models to the predominant clinical and payer dynamics of each geography to achieve sustainable adoption.

Competitive and strategic company insights identifying capability strengths partnership opportunities regulatory differentiators and gaps within the PMS treatment ecosystem

Competitive positioning within the premenstrual syndrome treatment ecosystem is defined less by single product breakthroughs and more by portfolio depth, evidence robustness, and cross-channel partnerships. Pharmaceutical companies with established portfolios in hormonal and neuro-modulatory classes retain advantages when they pair clinical trial outcomes with real-world adherence programs and clinician engagement. At the same time, specialist nutraceutical manufacturers and contract developers that can demonstrate consistent sourcing, batch-to-batch quality, and clinical-grade formulation are increasingly attractive to both clinicians and large-scale distributors. Technology-enabled providers-ranging from teletherapy platforms to digital symptom trackers-are differentiating through integration capabilities that link behavioral interventions with clinical oversight and data capture.

Strategic collaborations between these constituents are becoming more common, as manufacturers seek to bundle pharmacological options with digital therapeutics or evidence-based supplementation to create comprehensive care pathways. Regulatory approvals, quality certifications, and transparent supply chain practices continue to be key differentiators, and companies that invest in comparative-effectiveness research and payer engagement are better positioned to influence procurement decisions. Ultimately, competitive advantage accrues to organizations that can align clinical credibility with scalable delivery and that can adapt product and service offerings to diverse end-user settings.

Actionable strategic recommendations for industry leaders to enhance adoption optimize access and deliver integrated value across PMS therapeutic and service offerings

Industry leaders should prioritize a set of coordinated actions that accelerate adoption, preserve access, and create durable value across clinical and commercial channels. First, investing in high-quality evidence that links interventions to functional outcomes will strengthen positioning with clinicians and payers and will facilitate integration into care pathways. Second, developing interoperable digital tools and telehealth-enabled programs that can be bundled with pharmacological or supplement offerings will improve adherence and support longitudinal outcome measurement. These capabilities should be complemented by robust manufacturing and supply chain strategies that reduce dependence on single-source imports and that enhance responsiveness to tariff or trade-policy shifts.

In addition, organizations ought to pursue cross-sector partnerships that combine pharmaceutical expertise, nutraceutical formulation, and digital engagement to offer multi-modal therapeutic packages that reflect real-world patient needs. Strategic market entry should be regionally tailored, with regulatory and reimbursement strategies aligned to local health system dynamics. Finally, operationalizing patient-centric product design-through adaptable dosing formats, palatable oral liquids, and user-friendly capsule or tablet options-will increase acceptance across home care, hospital, and specialty clinic settings, thereby improving real-world uptake and clinical impact.

Transparent multi-method research methodology outlining data collection triangulation expert validation and analytical frameworks underpinning the PMS treatment analysis

This analysis was developed using a multi-method research approach that prioritized triangulation and validation across primary and secondary sources. Primary inputs included structured interviews with clinicians, pharmacy leaders, procurement specialists, and technology providers to capture frontline perspectives on therapeutic effectiveness, delivery challenges, and adoption drivers. Secondary sources encompassed peer-reviewed clinical literature, regulatory guidance documents, product labeling, and publicly available clinical trial registries to corroborate mechanism-of-action, safety profiles, and therapeutic positioning. Data synthesis relied on thematic analysis to identify recurring patterns and on comparative assessment to surface region-specific distinctions.

Analytical rigor was maintained through iterative validation cycles, wherein preliminary findings were reviewed with domain experts to refine assumptions and to identify potential bias. Supply chain and policy impacts were assessed through scenario analysis that considered tariff-related logistics, sourcing alternatives, and procurement responses, with attention to operational feasibility. The methodology emphasizes transparency in source attribution and contextual caveats so that stakeholders can judge the applicability of findings to their strategic questions and regional contexts.

Concluding synthesis integrating clinical trends regulatory influences and commercial signals to define pragmatic next steps for stakeholders in PMS care

In synthesis, the evolving landscape for premenstrual syndrome treatment is defined by a move toward integrated, patient-centered care that blends behavioral, nutraceutical, and pharmacological approaches. Clinical and delivery innovations are expanding the range of viable interventions while also raising the bar for evidence, quality, and interoperability. Policy and trade factors have highlighted the need for resilient supply chains and adaptive procurement strategies, and regional differences in regulation and care models underscore the necessity of tailored plans rather than one-size-fits-all rollouts.

Looking ahead, stakeholders who invest in rigorous outcome measurement, who build flexible product portfolios spanning capsules, oral liquids, and tablets, and who leverage digital platforms to support adherence will be best positioned to meet clinician and patient expectations. Collaboration across pharmaceutical, nutraceutical, and digital health domains will be essential to convert clinical promise into practical, scalable care. Ultimately, the most successful strategies will be those that balance scientific credibility with operational agility and that deliver demonstrable improvements in daily functioning for individuals affected by premenstrual syndrome.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Premenstrual Syndrome Treatment Market, by Treatment Type

  • 8.1. Non Pharmacological Treatment
    • 8.1.1. Cognitive Behavioral Therapy
    • 8.1.2. Lifestyle Management
    • 8.1.3. Nutritional Supplements
      • 8.1.3.1. Amino Acid Derivatives
      • 8.1.3.2. Herbal Extracts
      • 8.1.3.3. Vitamins & Minerals
  • 8.2. Pharmacological Treatment

9. Premenstrual Syndrome Treatment Market, by Product Form

  • 9.1. Capsule
  • 9.2. Oral Liquid
  • 9.3. Tablet

10. Premenstrual Syndrome Treatment Market, by End User

  • 10.1. Home Care Settings
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Premenstrual Syndrome Treatment Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Premenstrual Syndrome Treatment Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Premenstrual Syndrome Treatment Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Premenstrual Syndrome Treatment Market

15. China Premenstrual Syndrome Treatment Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Bayer AG
  • 16.6. Eli Lilly and Company
  • 16.7. GlaxoSmithKline plc
  • 16.8. Johnson & Johnson Services, Inc.
  • 16.9. Novartis AG
  • 16.10. Pfizer Inc.
  • 16.11. Sanofi S.A.
  • 16.12. Sun Pharmaceutical Industries Ltd.
  • 16.13. Teva Pharmaceutical Industries Ltd.
  • 16.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY LIFESTYLE MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY AMINO ACID DERIVATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HERBAL EXTRACTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY VITAMINS & MINERALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY ORAL LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 108. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 109. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 110. GCC PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 126. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 127. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 128. G7 PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 132. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 133. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 134. NATO PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY PRODUCT FORM, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA PREMENSTRUAL SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)